Objective  To establish the criteria for drug utilization evaluation (DUE) of bemiparin sodium, and to analyze and comprehensively evaluate the clinical application status of bemiparin sodium in a hospital.

Methods  With the drug package insert as the core reference, the detailed DUE criteria for bemiparin sodium were formulated through literature research and expert consultation using the Delphi method. Then, the rational drug use was evaluated in the medical records of inpatients receiving bemiparin sodium in the hospital, and off-label medication was assessed for evidence using the Thomson classification system of Micromedex database.

Results  A total of 168 medical records were included, among which 78 cases (46.43%) were fully consistent with the DUE criteria. The main types of irrational drug use were unregistered off-label use (23.21%, 39/168), inappropriate dosage and administration (11.31%, 19/168), and inappropriate administration timing (5.95%, 10/168). The incidence of adverse drug reactions was 3.57% (6/168), dominated by bleeding events, including gastrointestinal bleeding, skin ecchymosis, and elevated liver enzymes. Off-label drug use mainly included off-label indi-cations and off-label populations.

Conclusion  The level of rational clinical use of bemiparin sodium in the hospital needs to be improved. The DUE criteria es-tablished in this study are scientific, practical and feasible. It is recommended to further standardize clinical use and strengthen off-label use management of bemiparin sodium.

1. Planès A. Review of bemiparin sodium-a new second generation low molecular weight heparin and its applications in venous thromboembolism[J]. Expert Opinion, 2003, 4(9): 1551-1561. DOI: 10.1517/14656566.4.9.1551.

2. Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis[J]. Drugs, 2003, 63(21): 2357- 2377. DOI:10.2165/00003495-200363210-00009.

3. Kakkar WV, Balibrea JL, Martinez-Gonzilez J, et al. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study[J]. J Thromb Haemost, 2010, 8(6): 1223-1229. DOI: 10.1111/j.1538-7836.2010.03892.x.

4. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients[J]. Chest, 2012, 141: e227S-e277S. DOI: 10.1378/chest.11-2297.

5. National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hos-pital-acquired deep vein thrombosis or pulmonary embolism. NICE guideline [NG89][R]. 2018: 1-40.

6. 中国老年医学学会重症医学分会, 浙江省重症医学临床医学研究中心. 老年重症患者静脉血栓栓塞症预防中国专家共识(2023)[J]. 中华危重病急救医学, 2023, 35(6): 561-572. [Critical Care Medicine Division of Chinese Geriatric Society, Zhejiang Provincial Clinical Research Center for Critical Care Medicine. Expert consensus on the prevention of venous thromboembolism for elderly patients with critical illness in China (2023)[J]. Chinese Critical Care Medicine, 2023, 35(6): 561-572. ] DOI: 10.3760/cma.j.cn121430-20230502-00329.

7. 柯义君, 王威, 金涌, 等. 依诺肝素钠药物利用评价标准的建立与应用[J]. 中国药物应用与监测, 2025, 22(5): 914-918. [Ke YJ, Wang W, Jin Y, et al. Establishment and application of drug use evaluation criteria for enoxaparin sodium[J]. Chinese Journal of Drug Application and Monitoring, 2025, 22(5): 914-918.] DOI: 10.3969/j.issn.1672-8157.2025.05.034.

8. 王芳芳, 陈锦珊, 陈国权, 等. 骨科那屈肝素药物利用评价标准的建立与应用[J]. 中国医院用药评价与分析, 2023, 23(3): 325-328, 338. [Wang FF, Chen JS, Chen GQ, et al. Establishment and application of drug use evaluation criteria of nadroparin in orthopedics[J]. Evaluation and Analysis of Drug-Use in Hospitals of China, 2023, 23(3): 325-328, 338.] DOI: 10. 14009 / j. issn. 1672-2124. 2023. 03. 016.

9. 田璐璐, 李美娟, 祝德秋, 等. 基于加权TOPSIS法的贝米肝素钠注射液药物利用评价[J]. 药物流行病学杂志, 2024, 33(5): 481-488. [Tian LL, Li MJ, Zhu DQ, et al. Drug use evaluation of bemiparin sodium injection based on weighted TOPSIS method[J]. Chinese Journal of Pharmacoepidemiology, 2024, 33(5): 481-488. ] DOI: 10.12173/j.issn.1005-0698.202306021.

10. 中国药师协会精准药学工作委员会, 《低分子肝素临床应用中国专家共识》编委会. 低分子肝素临床应用中国专家共识[J]. 中国现代应用药学, 2026, 43(4): 547-565. [Precision Pharmacy Working Committee of the Chinese Pharmacist Association, Expert Panel of the Chinese Expert Consensus on the Clinical Application of Low Molecular Weight Heparins. Chinese expert consensus on the clinical application of low molecular weight heparin[J]. Chinese Journal of Modern Applied Pharmacy, 2026, 43(4): 547-565.] DOI: 10.13748/j.cnki.issn1007-7693.20252043.

11. 《中国血栓性疾病防治指南》专家委员会. 中国血栓性疾病防治指南[J]. 中华医学杂志, 2018, 98(36): 2861-2888. DOI: 10.3760/cma.j.issn.0376-2491.2018. 36.002.

12. 中华医学会外科学分会. 中国普通外科围手术期血栓预防与管理指南[J]. 中华外科杂志, 2016, 54(5): 321-327. DOI: 10.3760/cma.j.issn.0529-5815.2016.05.001.

13. 中华医学会骨科学分会创伤骨科学组, 中华医学会骨科学分会外固定与肢体重建学组中国医师协会骨科医师分会创伤专家工作委员会, 创伤感染专家委员会, 等. 中国创伤骨科患者围手术期静脉血栓栓塞症预防指南(2021)[J]. 中华创伤骨科杂志, 2021, 23(3): 185-192. [Traumatic Orthopedics Group, Society of Orthopedics, Chinese Medical Association; Group of External Fixation and Limb Reconstrucction, Society of Orthopedics, Chinese Medical Association; Trauma Expert Working Committee, Society of Orthopedics, Association of Chinese Doctors; et al. Guidelines for prevention of perioperative venous thromboembolism in Chinese orthopedic trauma patients (2021)[J]. Chinese Journal of Orthopaedic Trauma, 2021, 23(3): 185-192.] DOI: 10.3760/cma.j.cn115530-20201228-00795.

14. 中国药师协会围手术期用药工作委员会. 围手术期静脉血栓栓塞症防治策略与药学监护专家共识[J]. 医药导报, 2025, 44(11): 1717-1735. [Perioperative Medication Working Committee of the Chinese Pharmacists Association. Expert consensus on perioperative strategies of VTE prevention and treatment,and pharmaceutical care[J]. Herald of Medicine, 2025, 44(11): 1717-1735. ] DOI: 10.3870/j.issn.1004-0781.2025.11.001.

15. 王乔宇,武明芬,柳鑫,等. 2021 中国静脉血栓栓塞症防治抗凝药物的选用与药学监护指南[J]. 中国临床药理学杂志, 2021, 37(21): 2999-3016. [Wang QY, Wu MF, Liu X, et al. Guidelines for the selection and pharmaceutical care of anticoagulants for the prevention and treatment of venous thromboembolism in China of 2021[J]. The Chinese Journal of Clinical Pharmacology, 2021, 37(21): 2999-3016.] DOI: 10.13699/j.cnki.1001-6821.2021.21.032.

16. 马雪, 何梦婕. 基于德尔菲法的儿童居家备药现状调查及安全用药评估体系构建[J]. 中国药业, 2026, 35(7): 17-22. [Ma X, He MJ. Investigation on the current status of children's home-stocked medications and construction of a safe medication evaluation system based on the Delphi method[J]. China Pharmaceuticals, 2026, 35(7):17-22.] DOI:10.3969/j.issn.1006-4931.2026.07.003.

17. 蒋媛媛, 郑桂梅, 曹耀华, 等. 临床药师主导的T2DM患者全周期管理模式构建[J]. 中国药房, 2026, 37(1): 92-98. [Jiang YY, Zheng GM, Cao YH, et al. Construction of a full-cycle management model for T2DM patients led by clinical pharmacists[J]. China Pharmacy, 2026, 37(1): 92-98.] DOI: 10.6039/j.issn.1001-0408.2026.01.17.

18. 广东省药学会. 超说明书用药循证评价规范. T/GDPA 1—2021[S]. 2021.

19. 中华医学会妇产科学分会产科学组, 复发性流产诊治专家共识编写组. 复发性流产诊治专家共识(2022)[J]. 中华妇产科杂志, 2022, 57(9): 653-667. DOI: 10.3760/cma.j.cn112141-20220421-00259.

20. 中华医学会血液学分会血栓与止血学组. 易栓症诊断与防治中国指南(2021年版)[J]. 中华血液学杂志, 2021, 42(11): 881-888. [Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis, prevention and treatment of thrombophilia (2021)[J]. Chinese Journal of Hematology, 2021, 42(11): 881-888.] DOI: 10.3760/cma.j.issn.0253-2727.2021.11.001.

21. Skeith L, Carrier M, Kaaja R, et al. A Meta-analysis of low molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia[J]. Blood, 2016, 127(13): 1650-1655. DOI: 10.1182/blood-2015-12-626739.

22. 赵久良, 沈海丽, 柴克霞, 等. 抗磷脂综合征诊疗规范[J]. 中华内科杂志, 2022, 61(9): 1000-1007. [Zhao JL, Shen HL, Chai KX, et al. Recommendations for management of antiphospholipid syndrome in China[J]. Chinese Journal of Internal Medicine, 2022, 61(9): 1000-1007.] DOI:10.3760/cma.j.cn112138-20211222-00907.

23. 中华医学会妇产科学分会产科学组. 妊娠期及产褥期静脉血栓栓塞症预防和诊治专家共识[J]. 中华妇产科杂志, 2021, 56(4): 236-243. DOI: 10.3760/cma.j.cn112141-20201110-00826

24. 四川省医学科学院·四川省人民医院, 电子科技大学医学院, 个体化药物治疗四川省重点实验室, 等. 儿童血栓性疾病防治药学实践指南[J]. 医药导报, 2024, 43(7):1017-1038. [Sichuan Academy of Medical Sciences & Sichuan Prorincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Personalized Dnig Therapy Key Laboratory of Sichuan Prorince, et al. Pharmacy practice guidelines for the prevention and treatment of thromboembolic diseases in children [J]. Herald of Medicine, 2024, 43(7): 1017-1038.] DOI: 10.3870/j.issn.1004-0781.2024.07.001.

25. Fontcuberta BJ. New frontiers with bemiparin: use in special populations[J]. Drugs, 2010, 14(70 Suppl 2): 43-47..https://www.nstl.gov.cn/paper_detail.html?id=b7229fe9f22e55fb6bb1ac84fa135043.

26. 曾于桦, 顾平, 张鹏. 某院骨科手术患者抗凝药物使用合理性分析[J].中国药业, 2024, 33(12): 120-123. [Zeng YH, Gu P, Zhang P. Rationality analysis of anticoagulant drug use among patients undergoing orthopedic surgery in a hospital[J]. China Pharmaceuticals, 2024, 33(12): 120-123.] DOI: 10.3969 / j.issn.1006-4931.2024.12.027.

27. Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline[J]. Ann Oncol, 202, 34(5): 452-467. DOI: 10.1016/j.annonc.2022.12.014.

28. 低分子肝素防治自然流产中国专家共识编写组. 低分子肝素防治自然流产中国专家共识[J]. 中华生殖与避孕杂志, 2018, 38(9): 701-708. [Chinese Experts Consensus Group on Low Molecular Weight Heparin for Prevention and Treatment of Spontaneous Abortion, China. Chinese experts consensus on prevention and treatment of spontaneous abortion with low molecular weight heparin[J]. Chinese Journal of Reproduction and Contraception, 2018, 38(9): 701-708.] DOI: 10.3760/cma.j.issn.2096-2916.2018.09.001.

29. 国家妇幼健康研究会生殖免疫学专业委员会专家共识编写组. 复发性流产抗血栓药物治疗中国专家共识[J]. 中华生殖与避孕杂志,2022,42(12):1207-1217. [Experts Consensus Group on Reproductive Immunology, Maternal and Child Health Research Association. Antithrombotic drug use for recurrent spontaneous abortion: a Chinese expert consensus[J]. Chinese Journal of Reproduction and Contraception, 2022, 42(12): 1207-1217. ] DOI: 10.3760/cma.j.cn101441-20220907-00385.

30. 国家妇幼健康研究会生殖免疫学专业委员会专家共识编写组. 复发性流产合并血栓前状态诊治中国专家共识[J]. 中华生殖与避孕杂志, 2021, 41(10): 861-875. [Experts Consensus Group on Reproductive Immunology, Maternal and Child Health Research Association. Chinese experts consensus on the diagnosis and treatment of recurrent spontaneous abortion with prethrombotic state[J].Chinese Journal of Reproduction and Contraception, 2021, 41(10): 861-875.] DOI: 10.3760/cma.j.cn101441-20210715-00310.

31. 广东省精准医学会血液分会出凝血青年专委会, 广东省易栓症多学科专家共识编写组. 广东省易栓症诊治多学科专家共识[J].岭南现代临床外科, 2023, 23(5): 367-378. [Guangdong Province Precision Medicine Association Hematology Branch Hemostasis Youth Committee, Expert Consensus Writing Group on the Diagnosis and Treatment of Thrombophilia in Guangdong Province. Expert consensus on the diagnosis and treatment of thrombophilia in Guangdong Province[J]. Lingnan Modern Clinics in Surgery, 2023, 23(5): 367-378. ] DOI: 10.3969/j.issn.1009-976X.2023.05.001.

32. 中国成人血小板减少症急诊管理共识专家组. 中国成人血小板减少症急诊管理专家共识[J]. 中华急诊医学杂志, 2022, 31(2): 161-168. DOI: 10.3760/cma.j.issn.1671-0282.2022.02.005.

33. Zhai Z, Kan Q, Li W, et al. VTE risk profiles and prophylaxis in medical and surgical inpatients: the identification of Chinese hospitalized patients' risk profile for venous thromboembolism (DissolVE-2)-across-sectional study[J]. Chest, 2019,155(1):114-122. DOI: 10.1016/j.chest.2018.09.020.